Literature DB >> 31678902

Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence.

Parunyou Julayanont1, Nikolaus R McFarland2, Kenneth M Heilman3.   

Abstract

OBJECTIVES: To identify the characteristics and prevalence of mild cognitive impairment in patients with motor-manifest Huntington's disease (HD) and to propose a new mild cognitive impairment (HD-MCI) classification for HD.
METHODS: We included 307 motor-manifest HD participants from the ENROLL-HD study who completed the evaluation in four neurocognitive domains including executive functions, processing speed, language, and memory. Cognitive impairment in each domain was determined by age- and education-adjusted cutoffs (> 1.5 standard deviations below the mean). HD-MCI was defined as an impairment in at least one cognitive domain without a loss of functional independence (Function Independence Scale, FIS ≥85). Dementia (HD-Dem) was defined as at least two domains of cognitive impairment with functional impairment (FIS ≤80).
RESULTS: At the onset of motor symptoms, MCI was present in 84% and dementia in 5% of patients. After 5 years of motor symptoms, 24% of participants met the criteria for MCI and 69% for dementia. Executive dysfunction was the most common impairment, being present in 70% of participants, followed by slowed processing speed in 67%. Language impairment was reported in 55% and memory deficits in 53%. MCI subtypes were classified as "Executive-predominant" (executive impairment and slowed processing speed), "Representational-predominant" (impaired language and memory) and "Mixed Executive-Representational". Executive-predominant MCI comprised 30%, Representational-predominant 15% and Mixed 55% of this cohort.
CONCLUSION: MCI is highly prevalent in the early stage of motor-manifest HD. Three MCI subgroups are defined suggesting at the earlier stage of this disease the frontal-striatal-executive and/or the temporoparietal-representational functional network can be impaired.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chorea; Cognitive disorders/dementia; Huntington's disease; Mild cognitive impairment

Year:  2019        PMID: 31678902     DOI: 10.1016/j.jns.2019.116523

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Amelioration of oxidative stress and neuroinflammation in lipopolysaccharide-induced memory impairment using Rosmarinic acid in mice.

Authors:  Chetan Thingore; Viplav Kshirsagar; Archana Juvekar
Journal:  Metab Brain Dis       Date:  2020-10-17       Impact factor: 3.584

2.  Does pallidal neuromodulation influence cognitive decline in Huntington's disease?

Authors:  Emily Sanrey; Valérie Macioce; Victoria Gonzalez; Laura Cif; Fabienne Cyprien; Emilie Chan Seng; Philippe Coubes; Gaetan Poulen
Journal:  J Neurol       Date:  2020-09-04       Impact factor: 4.849

3.  Brain, cognitive, and physical disability correlates of decreased quality of life in patients with Huntington's disease.

Authors:  Estefanía Junca; Mariana Pino; Hernando Santamaría-García; Sandra Baez
Journal:  Qual Life Res       Date:  2022-08-17       Impact factor: 3.440

4.  Hydrogen Sulfide Ameliorates Lipopolysaccharide-Induced Memory Impairment in Mice by Reducing Apoptosis, Oxidative, and Inflammatory Effects.

Authors:  Viplav Kshirsagar; Chetan Thingore; Malvika Gursahani; Nitin Gawali; Archana Juvekar
Journal:  Neurotox Res       Date:  2021-05-22       Impact factor: 3.911

5.  Mild Cognitive Impairment as an Early Landmark in Huntington's Disease.

Authors:  Ying Zhang; Junyi Zhou; Carissa R Gehl; Jeffrey D Long; Hans Johnson; Vincent A Magnotta; Daniel Sewell; Kathleen Shannon; Jane S Paulsen
Journal:  Front Neurol       Date:  2021-07-07       Impact factor: 4.003

6.  The Expanding Therapeutic Potential of Neuronal KCC2.

Authors:  Bor Luen Tang
Journal:  Cells       Date:  2020-01-17       Impact factor: 6.600

7.  Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life.

Authors:  Leonard L Sokol; Jonathan P Troost; Benzi M Kluger; Allison J Applebaum; Jane S Paulsen; Danny Bega; Samuel Frank; Joshua M Hauser; Nicholas R Boileau; Colin A Depp; David Cella; Noelle E Carlozzi
Journal:  Ann Clin Transl Neurol       Date:  2021-07-20       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.